Sleep medicine platform for universal diagnosis and treatment of sleep disorders

• Grant number: 22/01701-1
• Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
• Start date: July 01, 2022
• End date: June 30, 2023
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Agreement: FINEP - PIPE/PAPPE Grant
• Principal Investigator: Tácito Mistrorigo de Almeida
• Grantee: Tácito Mistrorigo de Almeida
• Company: Biologix Sistemas Ltda
• CNAE: Desenvolvimento e licenciamento de programas de computador customizáveis
• City: São Paulo
• Associated researchers: Geraldo Lorenzi Filho

Abstract

Obstructive Sleep Apnea (OSA) is a disease characterized by recurrent partial or complete obstructions of the upper respiratory airways during sleep, leading to intermittent hypoxia, fragmented sleep, decreased attention and increased cardiovascular risk. OSA is an extremely common disease. In Brazil, 40 million people have some degree of OSA and, worldwide, more than 1 billion. Most of them (85% in the US and 95% in Brazil) remain undiagnosed. Since 2015, Biologix has been a technology-based company dedicated to the development and market introduction of solutions for the diagnosis and monitoring of sleep apnea at home using wearable IoT sensors (wearables), an application for mobile devices and cloud computing. Currently, both technical and commercial results prove to be successful with the business model between companies and customers (B2B2C). However, despite this success, Biologix's interest in popularizing the diagnosis of obstructive sleep apnea is in its early stages, especially in relation to the B2C model. Thus, the objective of this Project is to achieve business development through the incorporation of technological innovations and the B2C model that will make it possible to popularize and democratize the access of the Brazilian population to the diagnosis and treatment of sleep disorders. Thus, the company intends to evolve the current solution, from (i) the development of a new virtual platform for mobile and fixed devices, which incorporates the patient's complete journey; (ii) the development of new sensors/devices; and (iii) the development of artificial intelligence algorithms to assist the professionals in decision making regarding the diagnosis and treatment of sleep apnea. (AU)